[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pharma Marketing 2020 (2016)

December 2015 | | ID: PB80350479AEN
FirstWord

US$ 695.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
How can pharma marketing effectively meet future communication challenges in a rapidly changing market place?

A shift in therapy decision making, the need for evidence to support brands and more informed patients are presenting diverse challenges for pharma marketing. What are the major communication pressures going forward? Is digital technology really the panacea for marketing communication? How should marketing teams be organised and outcomes assessed? Between the sales, medical and market access functions, what role can – or should - marketing play in the future?

Pharma Marketing 2020: Drivers of change analyses the operational challenges marketers face and examines solutions that will underpin solid, integrated marketing strategies. The report draws on the detailed and incisive insights of 7 marketing professionals working in leading companies in Europe and the US. This report identifies the issues that pharma marketers must address now!

“Probably the singular most significant change in terms of driving the marketing role is the ever-increasing focus on the value proposition of the drug.”

Answering key questions:
  • Richer messaging: The demand for brand propositions to be supported by clinical and real world evidence will grow and requires refined and expert communications -what role does marketing play?
  • It’s all about the patients: Patients are better informed about their condition and influential in therapy choice, at least in the US. How can marketing benefit from a deeper understanding of patient experience, behaviours and needs?
  • Face to face: The dash for digital will not replace the benefit of face-to-face communications with payers and physicians: can marketing be more efficient in effectively supporting these interactions?
  • Digital Marketing: How can you integrate multichannel digital initiatives into your marketing mix in a way that delivers content/communications when and where the user wants?
  • Push and Pull: When – and in what form - do you push information out? What are the benefits of enabling patients, payers and physicians to pull information on demand?
  • Team structure: How might organisational structures need to develop for marketing to work effectively in cross functional teams and deliver sophisticated specialty marketing services?
With this report you will be able to:
  • Understand the fundamental pharma market developments that are challenging current marketing practice and driving change
  • Develop strategies and tactics which support value-based propositions for your brands to health payers and other stakeholders
  • Assess the benefits and limitations of digital marketing and identify where it fits best into the marketing mix
  • Appreciate the growing influence of patients and develop marketing strategies that meet their needs
  • Critically appraise current data collection and analysis to ensure it provides on-target decision support knowledge
  • Support customer facing colleagues with specific and appropriate messages and marketing collateral
  • Know where specialty marketing will sit within the cross functional team and address the necessary organisational changes
Key Topics explored
  • Who are the pharmaceutical industry’s customers? The influence of physicians – at one time the gold standard contact – is waning with payers and medicines managers now in the decision making driving seat
  • The demise of the customer facing rep has long been forecast, but nothing can replace the value of personal interaction. Digital communications will play an increasing role in extending and expanding the scope and value of customer facing staff
  • There has been a rush to develop digital communications, but much of it has failed to either engage the audience or deliver the right content. Getting this right will be critical going forward
  • There is a marked difference in patient attitudes and knowledge between patients in the US and Europe – what lessons are there for marketers?
  • Meeting the needs of multiple stakeholders via multi-channel communication when much traditional marketing spend has been reallocated – can it be done?
  • Valuable local knowledge is being lost with the centralisation of marketing strategy and planning
Expert Contributors
  • Digital Multichannel Marketing Strategist, Top 10 pharma company
  • Senior Manager, Marketing Communications & Digital Marketing, Top 10 pharma company
  • Head of Global Marketing, Top 20 pharma company
  • Business Development Manager, Top 10 pharma company
  • Marketing Director, Top 20 pharma company
  • Sales Director, Top 20 pharma company
  • Sales & Marketing Manager, EU pharma company
  • Peter Dumovic, Pharmaceutical Consultant
About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1 EXECUTIVE

2 SUMMARY

3 METHODOLOGY AND OBJECTIVES

4 CONTRIBUTORS

5 OVERVIEW

6 HOW WILL PHARMA MARKETING EVOLVE?

6.1 Changes to the customer dynamic
    6.1.1.1 Trends
  6.1.1 The rising importance of payers as decision-makers
    6.1.1.2 The value proposition will become a greater challenge
  6.1.2 Patients’ influence on marketing practices
    6.1.1.3 Patient involvement in treatment decisions
    6.1.1.4 Gaining a deeper understanding of patients
  6.1.3 Customer centricity
    6.1.1.5 Where does pharma stand on customer centricity?
    6.1.1.6 Companies will get better at customer centricity
  6.1.4 Companies continue to focus marketing budgets on physicians
6.2 Changes to the marketing channel mix
    6.2.1.1 Trends
  6.2.1 Optimising the channel mix for customers
    6.2.1.2 More integrated marketing plans
    6.2.1.3 Face-to-face interaction will remain valuable
  6.2.4 Advancing digital marketing capabilities
    6.2.1.5 Traditional and social media marketing converge at medical meetings
    6.2.1.6 Striking a balance between push and pull marketing
    6.2.1.7 Partnering with established mHealth platforms
  6.2.5 Innovation and value-added solutions
6.3 Data, analysis and monitoring performance
    6.3.1.1 Trends
  6.3.1 Collecting data and measuring customer experience
    6.3.1.2 Why is customer experience monitoring important?
  6.3.2 Is marketing becoming better informed?
  6.3.3 Measuring outcome
6.4 Changes in team structure
    6.4.1.1 Trends
  6.4.1 Cross-functional brand teams
  6.4.2 Team organisation at global and local levels
  6.4.3 Will teams be organised around customer segments in the future?
  6.4.4 More sophisticated marketers will be required
6.5 Changes in budget allocation
    6.5.1.1 Trends
  6.5.1 Increased investment in market access
  6.5.2 Medical communication rather than promotion
6.6 Marketing trends and challenges
  6.6.1 Key trends that are shaping pharma marketing


More Publications